From 1 June 2025, every nurse and midwife prescriber working in non-surgical aesthetics must conduct a face-to-face consultation before issuing any prescription for elective cosmetic procedures. The Nursing and Midwifery Council updated its professional standards to make in-person assessment a binding requirement, and remote prescribing for cosmetic injectables is no longer compatible with NMC registration.
What the NMC's Updated Position Actually Says
The NMC announced the position update in early 2025, with the standard taking effect on 1 June 2025. The change is not a new law. Remote prescribing for cosmetic procedures was never prohibited under the Human Medicines Regulations 2012. What changed is the NMC's professional standard, which functions differently.
Professional standards set by the NMC are binding on all registrants. Practising in a way that is inconsistent with those standards creates a professional conduct risk. A nurse or midwife prescriber who continues remote prescribing for cosmetic injectables after 1 June 2025 is not breaking statute. They are, however, practising in a way the NMC considers incompatible with safe and ethical prescribing, which means any complaint can be referred directly to a Fitness to Practise panel.
The distinction matters because practitioners sometimes read "not illegal" as "therefore acceptable". In this case, it is not.
Which Prescriptions Fall Within Scope
The NMC's updated position covers all prescription-only medicines used in an elective, non-surgical cosmetic context. The most commonly encountered:
- Botulinum toxin (all formulations used for cosmetic indication)
- Hyaluronidase used to dissolve dermal filler
- Injectable local anaesthetics used in aesthetic procedures
- Prescription-strength topical anaesthetics used before non-surgical procedures
- Topical adrenaline held as part of an emergency protocol at an aesthetic clinic
The scope therefore reaches further than the obvious injectable. A prescriber issuing a prescription for topical anaesthetic to be used before a non-surgical procedure must now have seen the patient face-to-face first.
What is explicitly not in scope: prescriptions issued in a clearly medical context for a therapeutic clinical indication unrelated to cosmetic treatment. If the same prescriber issues a prescription for a skin condition being managed clinically, the cosmetic prescribing standard does not govern that episode. The line in practice is sometimes blurred, and prescribers should consider carefully which context governs each encounter.
Why the NMC Changed Its Position
The update was not unprompted. Three converging pressures drove it.
The direction of UK aesthetics regulation. The England licensing scheme has been moving the sector toward formalised, in-person clinical governance since the Health and Care Act 2022 received Royal Assent. The NMC position aligns the professional standard for nurse prescribers with what is expected of the sector more broadly. Regulators across the system have been watching one another and moving in the same direction.
Patient safety evidence. The JCCP has documented the risks associated with prescribing without direct clinical assessment, including missed contraindications, incorrect assessment of facial anatomy, and consent that cannot be genuinely informed without a physical examination. These are not theoretical harms. They have resulted in serious adverse events in clinical practice.
Comparator regulation. The Care Quality Commission, the General Medical Council, and the General Dental Council all have frameworks that expect in-person assessment before elective aesthetic prescribing in regulated settings. The NMC position had been something of an outlier. The updated standard corrects that alignment.
What a Compliant Face-to-Face Consultation Requires
The NMC has not published a detailed procedural checklist, but the standard implies the following must occur at or before each prescribing episode:
Direct clinical assessment. The prescriber must examine the patient. For most cosmetic injectable indications this means assessment of facial anatomy, skin quality, and the presenting area. This cannot be done reliably via video call.
Medical history review. A full medication and medical history must be taken and reviewed in person. This is standard prescribing practice but the NMC's position makes explicit that it cannot be completed satisfactorily by a remote questionnaire alone, particularly where a cosmetic context may create motivation to minimise relevant history.
Documented informed consent. The Aesthetics Journal notes that the NMC considers face-to-face consultation material to obtaining consent that meets the Montgomery standard, which requires the prescriber to disclose all risks a reasonable patient would consider significant. A consent form completed remotely, without direct discussion, is unlikely to meet this bar.
Clear documentation. The consultation and prescribing decision must be recorded in the patient's notes in a way that evidences the face-to-face assessment occurred. A note that reads only "reviewed questionnaire and issued prescription" does not demonstrate compliance.
The requirement applies to each prescribing episode. A single in-person consultation at the start of a patient's treatment history, with subsequent prescriptions issued remotely, does not satisfy the standard. Each time a prescription is issued, the in-person assessment must have preceded it.
How This Sits Alongside the England Licensing Scheme
The NMC prescribing standard and the England licensing scheme are parallel developments, not the same requirement. Understanding both is necessary for any nurse prescriber working in aesthetics.
The licensing scheme, once fully operational, will require practitioners performing certain non-surgical procedures to hold a licence issued by local authorities. Licensing will not replace professional regulation. It will layer on top of it.
A nurse prescriber therefore faces two distinct obligations:
NMC professional standard. Prescribing must follow the in-person consultation requirement. This applies now, across the UK, to all NMC registrants.
Licensing scheme. Carrying out licensable procedures in England will require a local authority licence. This applies when the scheme is enacted in each relevant local authority area.
These are governed by different bodies, enforced through different mechanisms, and a failure in one does not automatically create a failure in the other. However, in practice, a complaint following a patient harm can trigger scrutiny across both frameworks simultaneously. Practitioners who understand both are better placed to structure their practice in a way that holds up on either front.
What Happens if a Nurse Prescriber Does Not Comply
The NMC's enforcement route is the Fitness to Practise process. A complaint can be made by a patient, a colleague, or another regulator. The JCCP is explicit in its guidance that it expects its registered practitioners to comply with NMC standards as part of maintaining their JCCP registration. A failure on the NMC front therefore creates exposure on the JCCP registration front as well.
A Fitness to Practise finding against a nurse prescriber in this context would likely result in a caution, conditions on practice, or, in serious cases, striking off. Striking off ends NMC registration and with it the ability to practise nursing at all, not only the aesthetic element.
For prescribers who have been operating remote prescribing services, the practical step required is not gradual. There is no phased implementation. The standard applied from 1 June 2025. Any prescription issued after that date for a cosmetic injectable procedure should have been preceded by a face-to-face assessment by the prescriber.
Practitioners who became aware of this update late, or who have not yet restructured their patient pathway, should review their records and consider seeking advice from their professional indemnity provider.
Prescriber-Led Versus Prescriber-Involved Models
Some nurse aesthetic businesses operate on a model where the treating injector is not a prescriber, and prescriptions are issued by a separate prescriber who does not see the patient directly. The NMC's updated position requires the prescriber to have conducted the face-to-face assessment themselves.
This has significant operational implications. If a clinic relies on a prescribing service where a remote prescriber issues all prescriptions without seeing patients, that model is no longer compatible with NMC registration. The prescriber must have direct, documented involvement in the clinical assessment.
This is not a subtle interpretation. The standard applies to the prescriber's own assessment, not an assessment conducted by a non-prescriber colleague. Relying on a note from a treating practitioner who did see the patient, then issuing a prescription based on that note without personal examination, does not satisfy the requirement.
What Practitioners Need to Do Now
Three areas require review for any NMC-registered prescriber working in aesthetics.
Your patient pathway. Does your current model include a face-to-face assessment by you before each prescribing episode? If you operate a remote model or rely on another clinician's notes, that model needs to change. Document when the change takes effect.
Your prescribing records. Review records from June 2025 forward. If there are episodes where a prescription was issued without documented face-to-face assessment by you, consider seeking advice from your indemnity provider before any complaint is made.
Your consent process. The NMC's position has implications for how consent is recorded. Ensure your records reflect an in-person discussion, not a remote questionnaire alone. The two can coexist, but the in-person component must be evidenced clearly.
For non-prescriber practitioners who work under a prescriber arrangement, the same audit applies. Check that your prescribing partner's process meets the standard. If it does not, you may need to review that arrangement.
If you are working through how prescribing governance, the licensing scheme, and professional standards interact in practice, the RAG Pathway is the four-week programme that covers all of it in the sequence practitioners actually need.
FAQ
Does the NMC's face-to-face requirement apply to repeat prescriptions for existing patients?
Yes. The standard applies to each prescribing episode, not each new patient relationship. A patient who has attended the clinic multiple times and received prescriptions remotely since June 2025 represents multiple instances where the standard was not met. The requirement is that the prescriber conducts a face-to-face assessment before each individual prescription.
Does the requirement apply if the treating practitioner is not the prescriber?
Yes, and this is where many clinic models require restructuring. The face-to-face assessment must be conducted by the prescriber. A prescriber who issues prescriptions based on notes from another clinician, without their own direct assessment, does not meet the standard. Delegation of the clinical assessment to a non-prescriber is not compliant.
Does this apply to hyaluronidase for dissolving filler?
The NMC's position covers all prescription-only medicines used in a non-surgical cosmetic context. Hyaluronidase prescribed to reverse dermal filler for cosmetic purposes falls within scope. The same in-person assessment requirement applies before the prescription is issued.
How does this interact with the England licensing scheme?
They are separate regulatory frameworks with different enforcement bodies. The NMC standard governs prescribing conduct and applies to all NMC registrants across the UK, now. The England licensing scheme governs who may perform certain non-surgical cosmetic procedures in England, once enacted by local authorities. A practitioner must comply with both but through separate compliance routes.
What if a patient refuses to attend in person?
A nurse prescriber cannot issue a prescription for non-surgical cosmetic treatment on the basis of a remote consultation alone, regardless of patient preference. If a patient declines in-person assessment, no prescription can be issued under the NMC standard. This is not a matter of clinical discretion.
Does this affect doctors and dentists working in aesthetics?
The NMC standard applies specifically to nurses and midwives who hold an independent prescriber qualification. Doctors and dentists are regulated by the GMC and GDC respectively, and should check their own regulators' positions on this point. The direction of travel across all three regulators has been consistent, but the NMC's June 2025 update is binding only on NMC registrants.